Ainnocence Unveils Innovative AI-enabled Platform for Antibody Affinity Maturation and GPCR Antibody Design Platform
Ainnocence unveils AI for antibody affinity and GPCR design via SentinusAI®. Mapping 59 GPCR families, 175 targets, and 444 indications for advanced drug design SAN FRANCISCO , CALIFORNIA, UNITED STATES, December 5, 2023 /EINPresswire.com/ -- Ainnocence …